4 October 2022 - Eli Lilly has announced that the MHRA has granted marketing authorisation for baricitinib – also known as Olumiant – for the treatment of severe alopecia areata in adult patients.

Marketing authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both used the Severity of Alopecia Tool (SALT) score and both met the primary endpoint among the proportion of patients.

Read Pharma Times article